Tags

Type your tag names separated by a space and hit enter

User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.
Patient Prefer Adherence 2013; 7:455-62PP

Abstract

BACKGROUNDAIM: In growth disorders, ensuring long-term growth hormone therapy (GHT) remains a challenge that might compromise the clinical outcome. Consequently, strategies aiming at alleviating the burden of daily injection might improve the treatment benefit. The study reported here was performed to assess the ease of use of Norditropin NordiFlex(®) (Novo Nordisk, Princeton, NJ, USA) compared with that of the devices previously used in children treated with GHT with recombinant somatropin.

METHODS

This Phase IV prospective, multicenter, open-label study was conducted in France. All patients received Norditropin NordiFlex for 6 weeks. Oral questionnaires were administered by the physician to the patients and/or the parents at inclusion and at the final visit.

RESULTS

This study included 103 patients aged between 6 and 17 years. The patients assessed Norditropin NordiFlex as significantly easier to use than their previous device (median value = 7.5, P < 0.001). Almost three-quarters of patients (64.4%) preferred Norditropin NordiFlex to their previous device. Among physicians and nurses, 73% assessed Norditropin NordiFlex training as "very easy" and 26% as "easy." Norditropin NordiFlex improved patient autonomy, with 41% of patients able to self-inject the treatment.

CONCLUSION

This study has shown that Norditropin NordiFlex is reliable, safe, and easy to use and most study patients preferred it to their previous device. These characteristics may improve the adherence to GHT.

Authors+Show Affiliations

Hôpital des Enfants, Toulouse.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23737664

Citation

Tauber, Maithé, et al. "User Assessment of Norditropin NordiFlex(®), a New Prefilled Growth Hormone Pen: a Phase IV Multicenter Prospective Study." Patient Preference and Adherence, vol. 7, 2013, pp. 455-62.
Tauber M, Jaquet D, Jesuran-Perelroizen M, et al. User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study. Patient Prefer Adherence. 2013;7:455-62.
Tauber, M., Jaquet, D., Jesuran-Perelroizen, M., Petrus, M., Bertrand, A. M., & Coutant, R. (2013). User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study. Patient Preference and Adherence, 7, pp. 455-62. doi:10.2147/PPA.S43460.
Tauber M, et al. User Assessment of Norditropin NordiFlex(®), a New Prefilled Growth Hormone Pen: a Phase IV Multicenter Prospective Study. Patient Prefer Adherence. 2013;7:455-62. PubMed PMID: 23737664.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study. AU - Tauber,Maithé, AU - Jaquet,Delphine, AU - Jesuran-Perelroizen,Monique, AU - Petrus,Marc, AU - Bertrand,Anne Marie, AU - Coutant,Regis, AU - ,, Y1 - 2013/05/24/ PY - 2013/6/6/entrez PY - 2013/6/6/pubmed PY - 2013/6/6/medline KW - adherence KW - ease of use KW - growth hormone therapy KW - injection devices KW - preference SP - 455 EP - 62 JF - Patient preference and adherence JO - Patient Prefer Adherence VL - 7 N2 - UNLABELLED: BACKGROUNDAIM: In growth disorders, ensuring long-term growth hormone therapy (GHT) remains a challenge that might compromise the clinical outcome. Consequently, strategies aiming at alleviating the burden of daily injection might improve the treatment benefit. The study reported here was performed to assess the ease of use of Norditropin NordiFlex(®) (Novo Nordisk, Princeton, NJ, USA) compared with that of the devices previously used in children treated with GHT with recombinant somatropin. METHODS: This Phase IV prospective, multicenter, open-label study was conducted in France. All patients received Norditropin NordiFlex for 6 weeks. Oral questionnaires were administered by the physician to the patients and/or the parents at inclusion and at the final visit. RESULTS: This study included 103 patients aged between 6 and 17 years. The patients assessed Norditropin NordiFlex as significantly easier to use than their previous device (median value = 7.5, P < 0.001). Almost three-quarters of patients (64.4%) preferred Norditropin NordiFlex to their previous device. Among physicians and nurses, 73% assessed Norditropin NordiFlex training as "very easy" and 26% as "easy." Norditropin NordiFlex improved patient autonomy, with 41% of patients able to self-inject the treatment. CONCLUSION: This study has shown that Norditropin NordiFlex is reliable, safe, and easy to use and most study patients preferred it to their previous device. These characteristics may improve the adherence to GHT. SN - 1177-889X UR - https://www.unboundmedicine.com/medline/citation/23737664/User_assessment_of_Norditropin_NordiFlex_®__a_new_prefilled_growth_hormone_pen:_a_Phase_IV_multicenter_prospective_study_ L2 - https://dx.doi.org/10.2147/PPA.S43460 DB - PRIME DP - Unbound Medicine ER -